CTLA4 and melanoma: The first‐in‐class monoclonal anti‐CTLA‐4 antibody ipilimumab (Yervoy; Bristol Myers Squibb) was the first ICI to gain FDA approval38 and has been shown to induce durable responses, allowing a subset (16–20%) of advanced stage IV melanoma patients to achieve stable disease.39